Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.50 |
| ▸ | HTR2C | P28335 | 11/20 | 0.45 |
| ▸ | HTR2A | P28223 | 9/20 | 0.45 |
| ▸ | HTR2B | P41595 | 8/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30038539 | 0.85 | HTR2C (0.58) | NOTUMHTR2CHTR2AHTR2BCYP1A2 | |
| SCHEMBL7972018 | 0.77 | HTR2C (0.58) | HTR2CHTR2AHTR2BCYP1A2LMNA | |
| SCHEMBL7373998 | 0.77 | NOTUM (0.59) | NOTUMHTR2CHTR2AHTR2BPOLB | |
| SCHEMBL7479611 | 0.77 | NOTUM (0.59) | NOTUMHTR2CHTR2AHTR2BPOLB | |
| SCHEMBL30038735 | 0.77 | HTR2C (0.55) | HTR2CHTR2AHTR2BCYP1A2LMNA | |
| SCHEMBL7083408 | 0.75 | NOTUM (0.57) | NOTUMHTR2CHTR2AHTR2BCYP1A2 | |
| SCHEMBL7086213 | 0.74 | HTR2C (0.59) | NOTUMHTR2CHTR2AHTR2BCYP1A2 | |
| SCHEMBL8141514 | 0.73 | LMNA (0.60) | NOTUMPOLBLMNATSHRSMN1; SMN2 | |
| SCHEMBL30039733 | 0.70 | NOTUM (0.52) | NOTUMHTR2CHTR2AHTR2BCYP1A2 | |
| SCHEMBL8130919 | 0.70 | NOTUM (0.54) | NOTUMPOLBRXFP1USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0912554-B1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2002-11-27 | — | — | EP | disclosed |
| US-6369060-B1 | CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS ANXIETY; 5-METHYL-6-TRIFLUOROMETHYL-1-(6-(2-METHYLPYRIDIN-3-YLOXY)-PYRIDIN-3-YL CARBAMOYL)INDOLINE AND 5-METHYL-1-(6-(2-METHYLPYRIDIN-3-YLOXY) -PYRIDAZIN-3-YLCARBAMOYL)-6-TRIFLUOROMETHYLINDOLINE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-09 | — | — | US | disclosed |
| US-20020035134-A1 | Indoline derivatives useful as 5-HT-2C receptor antagonists | SMITHKLINE BEECHAM P.L.C. | 2002-03-21 | — | — | US | disclosed |
| US-6313145-B1 | FOR THERAPY OF ANXIETY AND/OR DEPRESSION | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-06 | — | — | US | disclosed |
| EP-0912556-B1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-10-04 | — | — | EP | disclosed |
| EP-0984956-A1 | INDOLINE DERIVATIVES AS 5HT2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-15 | — | — | EP | disclosed |
| EP-0912556-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998052943-A1 | INDOLINE DERIVATIVES AS 5HT2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-26 | — | — | WO | disclosed |
| WO-1997048700-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035134-A1 | Indoline derivatives useful as 5-HT-2C receptor antagonists | HTR2C, HTR1A, HTR1D | NOTUM 4029/4885HTR2C 1/4885HTR2A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.